💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, priced for perfection — but flagged on governance.
Ind Swift Laboratories is scored on the pharma / healthcare framework. It keeps a slim 6.2% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -1.58×) — worth a closer look. Free cash flow is worth about -4.7% of its market value.
Over the last 3 years revenue compounded at -18%/yr and profit at -4%/yr. Book value itself has compounded 27%/yr — the hallmark of a genuine compounder. Return on equity is a weak 6.2%. In the latest quarter profit grew 39% versus the prior quarter.
At 67× earnings, the stock sits at the 95th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price implies ~17%/yr earnings growth for a decade. The forensic screen raises 3 red flags: Only ₹-0.07 of cash per ₹1 profit over 4 years — earnings not converting to cash; 93% of pre-tax profit is other income, not operations; Share count up 41% over 4 years — heavy equity dilution.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 36.17 | — | — |
| P/B | 2.05 | 4.1 | better |
| EV/EBITDA | 20.32 | 19.33 | worse |
| ROE | 6.22 | — | — |
| ROCE | 7.76 | 14.41 | worse |
| ROA | 4.71 | 1.64 | better |
| Quick Ratio | 3.22 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Negative CAGR — the top line has shrunk over this window. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (-3% vs -18%) — margin expansion is at work. The latest year saw a -83% swing — check if it's a one-off or structural.
Operating margins have been stable around 7% — no major structural shift. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line.
ROE at 3% — modest; the capital isn't working hard.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (-3% vs -14%) — share dilution is eroding per-share value. -14% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
3 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 25% sequentially — momentum is building. Wide quarterly swings (31% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 28% above earlier ones.
Profit jumped 39% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (5% → 14%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 42.9% — dispersed ownership; institutional flows drive the stock. FIIs trimmed 3.0pp — foreign money is rotating out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.